NorthCrest Asset Manangement LLC Sells 238 Shares of DexCom, Inc. $DXCM

NorthCrest Asset Manangement LLC cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 1.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,687 shares of the medical device company’s stock after selling 238 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in DexCom were worth $1,964,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock valued at $3,240,763,000 after acquiring an additional 925,882 shares during the last quarter. Jennison Associates LLC increased its stake in shares of DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after acquiring an additional 2,879,489 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after acquiring an additional 1,868,241 shares during the last quarter. Nuveen LLC bought a new stake in shares of DexCom in the 1st quarter valued at about $554,893,000. Finally, Raymond James Financial Inc. increased its stake in shares of DexCom by 21.8% in the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock valued at $229,117,000 after acquiring an additional 601,088 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on DXCM shares. Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. William Blair raised DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. UBS Group increased their target price on DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Finally, Mizuho increased their target price on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.89.

DexCom Trading Down 0.9%

NASDAQ:DXCM opened at $75.78 on Friday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The business has a 50 day moving average price of $80.22 and a two-hundred day moving average price of $78.39. The company has a market cap of $29.72 billion, a P/E ratio of 52.63, a price-to-earnings-growth ratio of 1.60 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm posted $0.43 EPS. The business’s revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. This represents a 5.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $88.99, for a total value of $130,459.34. Following the transaction, the executive vice president directly owned 106,689 shares of the company’s stock, valued at approximately $9,494,254.11. This trade represents a 1.36% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,315 shares of company stock worth $689,431. Insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.